Disease-modifying antirheumatic and immunoregulatory agents.
作者信息
Rainsford K D
出版信息
Baillieres Clin Rheumatol. 1990 Dec;4(3):405-32. doi: 10.1016/s0950-3579(05)80002-0.
PMID:2093435
Abstract
摘要
相似文献
1
Disease-modifying antirheumatic and immunoregulatory agents.
Baillieres Clin Rheumatol. 1990 Dec;4(3):405-32. doi: 10.1016/s0950-3579(05)80002-0.
2
Role of disease-modifying antirheumatic drugs versus cytotoxic agents in the therapy of rheumatoid arthritis.
Am J Med. 1988 Oct 14;85(4A):39-44. doi: 10.1016/0002-9343(88)90361-0.
3
Management of early inflammatory arthritis. Intervention with immunomodulatory agents: new pharmacological developments.
Baillieres Clin Rheumatol. 1992 Jun;6(2):455-84. doi: 10.1016/s0950-3579(05)80185-2.
4
The mechanism of action of antirheumatic agents.
Triangle. 1979;18(2-3):63-73.
5
The 11th Bristol-Myers Squibb Nagoya International Cancer Treatment Symposium. Cytokines and New Anticancer Agents on the Horizon of Oncology. Nagoya, Japan, 24-25 November 1995.
Cancer Chemother Pharmacol. 1996;38 Suppl:S1-119.
6
7
Leflunomide: a new DMARD for rheumatoid arthritis.
Hosp Med. 2000 May;61(5):344-7. doi: 10.12968/hosp.2000.61.5.1334.
8
[Present and future therapeutic strategies in rheumatoid arthritis].
Z Rheumatol. 1993 Nov-Dec;52(6):365-82.
9
The use of disease modifying antirheumatic drugs in the management of rheumatoid arthritis.
Postgrad Med J. 1989 Dec;65(770):905-12. doi: 10.1136/pgmj.65.770.905.
10
Disease-modifying antirheumatic drugs.
Med J Aust. 1992;157(11-12):797-801. doi: 10.5694/j.1326-5377.1992.tb141291.x.
Zotero 插件